medigraphic.com
Órgano de Difusión de la Asociación Académica Panamericana de Medicina Familiar A.C.

2005, Number 3

<< Back Next >>

Arch Med Fam 2005; 7 (3)

Pharmacological Treatment of High Blood Pressure in Primary Care: Part Two

Ramírez–Villaseñor I

Language: Spanish
References: 27
Page: 99-107
PDF size: 153.26 Kb.


Text Extraction

No Abstract


REFERENCES

  1. Green L. JNC 7 express: New thinking in hypertension treatment. (editorial). Am Fam Physician 2003; 68 (2):228-230.

  2. Woodwell DA. National ambulatory medical care survey: 1996 summary. Adv data 1997;295:1-25.

  3. Chobanian VA. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA, 2003; 289 (19):2560-2571.

  4. Phillips LS, Branch WT, Cook CB. Clinical inertia. Ann Intern Med. 2001;135:825-834.

  5. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension. 2000;35:544-549

  6. Oates JA. Antihypertensive agents and the drug therapy of hypertension. En: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman & Gilman's The Pharmacological Basis Of Therapeutics. 9th edition. New York, USA: McGraw-Hill; 1996. p. 780-808.

  7. Skolnik AS, Beck JD, Clark M. Combination antihypertensive drugs: recommendations for use. Am Fam Physician 2000;61 (10):3049-3056.

  8. Margo KL, Luttermoser G, Shaughnessy AF. Spironolactone in lef-sided heart failure: How does it fit in?. Am Fam Physician 2001; 64 (8): 1393-1398.

  9. Magill KM, Gunning K, Saffel-shrier S. New Developments in the management of hypertension. Am Fam Physician 2003; 68 (5):853-858.

  10. Weir MR. Angiotensin-II receptor antagonists: a new class of antihypertensive agents. Am Fam Physician 1996;53 (2):589-594.

  11. Kaplan NM. Angiotensin II receptor antagonists in the treatment of hypertension. Am Fam Physician 1999;60 (4):1185-1190.

  12. Bicket D. Using ACE inhibitors appropriately. Am Fam Physician 2002;66 (3):461-468

  13. Anastasio GD, Cornell KO, Menscer D. Drug interactions: Keeping it straight. Am Fam Physician 1997;56 (3):883-894

  14. Kirk JK. Angiotensin-II receptor antagonistas: Their place in therapy. Am Fam Physician 1999;59 (11):3140-3147.

  15. Moser M, Prisant LM. Low-dose combination therapy in hypertension (editorial). Am Fam Physician 1997; 56 (5):1275-1282

  16. Bakris GL. Improving prognosis of non-diabetic chronic renal insufficiency: the role of ACE inhibitors. Kidney Int. (citado por Bicket D referencia no. 16.).

  17. Scow TD, Smith GE, Shaughnessy FA. Combination therapy with ACE inhibitors and angiotensina-receptor blocker in heart failure. Am Fam Physician 2003; 68 (9):1795-1798.

  18. Straka RJ, Swanson AL. Calcium channel antagonists: Morbidity and mortality- What’s the evidence. Am Fam Physician 1998;57 (7):1551-1560.1

  19. Furnerg CD, Wright JT, Davis BR, Cutler JA, Alderman M, Black H, et al. Major outcomes in high-risk hypertensive patients randomized to angiotensina-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Anttihypertensive and Lipid-lowering Treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; (23)288:2981-2997.

  20. Ramírez-Villaseñor I, Menchaca-Cota J, Rosas-Rosales A. Sistema para el control de hipertensión arterial: experiencia en una unidad de medicina familiar de Guadalajara, México. Arch Med Fam 2004; 6(1):14-19.

  21. Sica Domenic A. Current concepts of pharmacotherapy in hypertension: Doxazosin –What does the future hold for it?. J Clin Hypertens. 2000;2 (3):222-224.

  22. Furberg CD. What trials are coming in hypertension and what trials should be done? 73rd Scientific Sessions of the American Heart Association; November 12-15, 2000; New Orleans, Lousiana.

  23. Sin autor. Aspectos económicos del medicamento. En: Baños-Diez JE, Farré-Albaladejo MG. Principios de farmacología clínica, Primera Edición. Barcelona, España: Masson; 2002: p. 261-269.

  24. Sin autor .Hipertensión arterial esencial. Guía diagnóstico terapéutica. Rev Med IMSS (Mex) 1997; 35 (6):411-436

  25. Morisky DE, Levine DM, Green LW. Five-year blood pressure control and mortality following health education for hypertensive patients. Am J Public Health 1983; 73 (2):153-162.

  26. García-Milián JA, Delgado-Martínez I. Promoción racional de medicamentos, una necesidad de estos tiempos. Rev Cubana Farm 2003;37 (1):2-6.

  27. Pérez-Peña J. Eficiencia en el uso de medicamentos. Rev Cubana de Farm 2003;37 (1)7-14.




2020     |     www.medigraphic.com